Comparing the current results to its competitors, Mesoblast Limited reported Revenue increase in the 4 quarter 2025 by 191.39 % year on year. The sales growth was above Mesoblast Limited's competitors' average revenue growth of 6.35 %, achieved in the same quarter.
Mesoblast Limited, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 109.79 %
Mesoblast Limited's Comment on Competition and Industry Peers
The competitive landscape includes the FDA-approved agent ruxolitinib for steroid-refractory acute graft-versus-host disease (GvHD) in patients aged 12 years and older. Mesoblast's product Ryoncil is approved for pediatric patients aged 2 months and older with steroid-refractory acute GvHD. The biotechnology and pharmaceutical industries are highly competitive, with many potential competitors, particularly large biopharmaceutical companies possessing greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. The market has experienced significant consolidation, concentrating resources among fewer competitors.
April 17, 2025
: In a noteworthy advancement for the field of regenerative medicine, Mesoblast Ltd has expanded payer coverage for its pioneering therapy, Ryoncil (remestemcel-L), to over 104 million U.S. lives. Despite this significant milestone, Mesoblast faces a challenging financial landscape, as evidenced by a marked decline in revenue in comparison to its competitors. This article delves into the implications of Ryoncil s expansive coverage and examines the financial hurdles confronting Mesoblast amidst a competitive industry backdrop. Mesoblast Ltd, a frontrunner in allogeneic cellular medicines, has achieved a significant breakthrough with its pivotal therapy, Ryoncil. Approved by the U.S. Food and Drug Administra...
March 27, 2025
On March 26, 2025, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a recognized global leader in allogeneic cellular therapies aimed at treating inflammatory diseases, announced the launch of Ryoncil (remestemcel-L) in the United States. This momentous occasion comes after Ryoncil became the first mesenchymal stromal cell (MSC) therapy to receive approval from the U.S. Food and Drug Administration (FDA) for any indication.Ryoncil represents a significant advancement in therapeutic options for patients suffering from various inflammatory conditions, enabling treatment avenues that were previously inaccessible. The approval by the FDA serves not only as a validation of the product s clinical efficacy and safety bu...
July 23, 2024
:This article discusses the recent acceptance of Mesoblast s Biologics License Application (BLA) by the US Food and Drug Administration (FDA) for the use of Ryoncil in the treatment of children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). If approved, Ryoncil will be the first allogeneic off-the-shelf cellular medicine in the US and the first cell therapy specifically indicated for children up to 18 years old with SR-aGVHD.Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a serious complication that can occur in children undergoing hematopoietic stem cell transplantation (HSCT). Despite advances in transplantation techniques, a significant proportion of pediatric patient...
November 21, 2023
Mesoblast Partners With BMT CTN on Pivotal Trial for Adults With SR-aGVHD In an exciting development for the treatment of inflammatory diseases, Mesoblast Limited has announced its partnership with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a pivotal trial for their lead product candidate, Ryoncil (remestemcel-L). This trial aims to evaluate the efficacy of Ryoncil in treating adults with steroid-refractory acute graft versus host disease (SR-aGvHD). The BMT CTN, composed of centers responsible for 80% of all US allogeneic Bone Marrow Transplants (BMTs), is funded by the United States National Institutes of Health (NIH). Mesoblast Limited, a global leader in allogene...
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of targeted alpha therapeutics for the treatment of cancer. Their business model revolves around harnessing the power of radiation to selectively kill cancer cells while sparing healthy tissues. By combining targeted alpha therapy with various cancer-targeting agents, they aim to develop innovative treatments that offer improved efficacy and reduced side effects for patients.
Sources:
Mesoblast Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mesoblast Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
